| Date Filed | Type | Description |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
4
| Silva Paul M (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Saltzman Edward C (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Reinsdorf Judith A (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Lacey David L. (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Kunkel Lori Anne (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| GREGORY JULIA P (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/02/2023 |
4
| Ring Christine (General Counsel) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 682 shares
@ $9.8763, valued at
$6.7k
Exercised 1,924 restricted stock units
@ $0 |
|
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/01/2022 |
4
| van Houte Hans (CFO) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 739 shares
@ $12.8805, valued at
$9.5k
Exercised 2,886 restricted stock units
@ $0 |
|
| 11/01/2022 |
4
| Ring Christine (General Counsel) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 699 shares
@ $12.8805, valued at
$9k
Exercised 1,924 restricted stock units
@ $0 |
|
| 11/01/2022 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 1,165 shares
@ $12.8805, valued at
$15k
Exercised 3,207 restricted stock units
@ $0 |
|
| 11/01/2022 |
4
| Wolff Stefani (EVP and COO) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 350 shares
@ $12.8805, valued at
$4.5k
Exercised 962 restricted stock units
@ $0 |
|
| 09/14/2022 |
4
| Saltzman Edward C (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $16.29, valued at
$814.5k
|
|
| 09/14/2022 |
3
| Saltzman Edward C (Director) has filed a Form 3 on Nurix Therapeutics, Inc. |
| 08/10/2022 |
4
| Ring Christine (General Counsel) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 40,199 options to buy
@ $18.5, valued at
$743.7k
|
|
| 08/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/10/2022 |
4
| van Houte Hans (CFO) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 120,000 options to buy
@ $18.5, valued at
$2.2M
|
|
| 08/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/10/2022 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 60,298 options to buy
@ $18.5, valued at
$1.1M
|
|
| 08/02/2022 |
4
| Ring Christine (General Counsel) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 712 shares
@ $15.67, valued at
$11.2k
Exercised 1,924 restricted stock units
@ $0 |
|
| 08/02/2022 |
4
| Wolff Stefani (EVP and COO) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 356 shares
@ $15.67, valued at
$5.6k
Exercised 962 restricted stock units
@ $0 |
|
| 08/02/2022 |
4
| van Houte Hans (CFO) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 752 shares
@ $15.67, valued at
$11.8k
Exercised 2,886 restricted stock units
@ $0 |
|
| 08/02/2022 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 1,186 shares
@ $15.67, valued at
$18.6k
Exercised 3,207 restricted stock units
@ $0 |
|
| 06/01/2022 |
4
| van Houte Hans (CFO) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Exercised 68,333 options to buy
@ $0.84, valued at
$57.4k
|
|
| 05/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|